Briefing

Featured article

JPM 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance

Also in this section

News in Numbers

Latest News

Latest Deals

01/22/2025 11:15:16
  • Home | The biggest challenges clinical trials will face in 2025
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Depth
  • The biggest challenges clinical trials will face in 2025
  • Investors optimistic about continued biotech and medtech IPO resurgence in 2025
  • ADCs breach barriers to become mainstream cancer treatment
  • WHO trial guidance goes beyond race and gender when tackling diversity
  • Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
  • From Davids to Goliaths: the GLP-1RA gold rush
  • Radiopharmaceutical trials face extra complexities due to nuclear red tape
  • PCI Pharma Services
  • Endress+Hauser
  • Listings
  • Events
  • Event: Digital Health Festival 2025
  • Pharmaceutical Technology Excellence Awards 2024 winners
  • Buyer's Guides
  • Next issue
01/22/2025 00:00:00